DIRECTORS REPORT

Dear Members,

Your directors have pleasure in presenting the **14th Annual report** on the affairs of the Company together with the Audited standalone and consolidated Statement of Accounts for the financial year ended on 31st March, 2024.

1. FINANCIAL PERFORMANCE OF THE COMPANY:

(Figure In Lakh (₹)

PARTICULARS	STANDALONE		CONSOLIDATED	
	2023-24	**2022-23**	**2023-24**	**2022-23**
Revenue from Operations	20,367.74	18,309.00	26,959.12	23,464.97
Other Income	283.04	238.40	288.10	244.55
Total Revenues	**20,650.78**	**18,547.40**	**27,247.22**	**23,709.52**
Profit before Financial Expenses, Preliminary expenses, Depreciation and Taxation	8130.34	6,857.50	14,726.79	12,019.61
Less: Financial expenses	710.35	448.19	710.35	448.19
Profit before Depreciation & Taxation	**7419.99**	**6,409.31**	**14.016.44**	**11,571.42**
Less: Depreciation & amortization expenses	422.19	181.10	422.19	181.10
Operating Profit before Other expenses & Taxation	**6997.80**	**6,228.21**	**13,594.25**	**11390.32**
Less: Other expenses	3,512.88	2,973.46	8400.91	6,678.59
Profit before Taxation	**3484.92**	**3,254.75**	**5,193.34**	**4711.73**
Less: Provision for Taxation Current Tax Deferred Tax	900.16 (0.70)	876.25 (38.44)	1330.14 -	845.49 -
Profit for the period	**2585.46**	**2,416.94**	**3,863.20**	**3866.24**

2. RESULT OF OPERATIONS AND STATE OF AFFAIRS:

During the fiscal year 2023-24 the total Standalone revenue of the Company stood at ₹ **2,03,67,74,002.60** and consolidated revenue stood at **₹2,69,59,12,431.89**.

The standalone profit of the Company in fiscal year ending on March, 31, 2024 has been reported as ₹ **25,85,46,436.68** and the consolidated profit is **₹38,63,20,137.37.**

3. TRANSFER TO RESERVES:

The Company has transferred Rs. **25,85,46,436.68** to Reserve and Surplus account by the end of fiscal year 2023-2024.

4. DIVIDEND:

The Board has not declared any Dividend during the financial year 2023-24.

5. STATE OF COMPANY'S AFFAIRS AND FUTURE OUTLOOK

Q-Line Biotech Pvt Ltd has been a trusted name in the diagnostics industry since its inception in 2010. The company specializes in the development, manufacturing, and distribution of diagnostic instruments, reagents, and consumables. Its product portfolio includes cutting-edge solutions in clinical chemistry, hematology, molecular diagnostics, rapid tests, ELISA, and more, catering to healthcare professionals and institutions across India. With a focus on innovation and quality, Q-Line Biotech has achieved ISO 13485 certification and operates advanced manufacturing facilities in Uttar Pradesh & Delhi, dedicated to producing in-vitro diagnostics (IVD) products aligned with the "Make in India" initiative.

The company's recent advancements include the development of molecular diagnostic kits for infectious diseases, such as RT-PCR kits for COVID-19, and innovative diagnostic tools like automated nucleic acid extraction systems. With a robust R&D setup, Q-Line Biotech is continually expanding its offerings to address emerging healthcare challenges and support the nation's healthcare objectives.

Your Directors are optimistic about the company's ability to sustain its growth trajectory through continued innovation, high-quality manufacturing, and a commitment to providing reliable, affordable, and accessible diagnostic solutions. The future outlook emphasizes strengthening R&D, expanding the product range, and contributing significantly to the healthcare ecosystem of India.

6. STATUTORY AUDITORS & AUDIT REPORT:

M/s Mayank Mehrotra & Associates, Chartered Accountants, Lucknow (Firm Registration Number 022941C) were appointed as the Statutory Auditors of the Company to hold office for a term of 05 years from the conclusion of the 12th Annual General Meeting held on 30th September, 2022 until the conclusion of the 17th Annual General Meeting of the Company to be held in the year 2027.

There are no qualifications or observations or remarks made by the Auditors in their Report. Hence, no comments are required to be made in the Directors Report.

7. DISCLOSURE OF FRAUD REPORTED BY AUDITOR UNDER SUB-SECTION (12) OF SECTION 143:

During the Financial Year 2023-24, no frauds were reported by the auditors under sub-section (12) of Section 143.

8. FINANCIAL STATEMENTS:

The audited Financial Statements of the Company, which form a part of this Annual Report, have been prepared in accordance with the provisions of the Companies Act, 2013, prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.

9. WEB ADDRESS WHERE ANNUAL RETURN HAS BEEN PLACED

Company has no website and consequently web-link of annual return is not disclosed in the Board's report.

10. DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TOTHE FINANCIAL STATEMENTS PURSUANT TO RULE 8 (5) (viii) OF COMPANIES (ACCOUNTS) RULES,2014:

The Company believes that strong internal control systems that are commensurate with the scale, scope and complexity of its operations are correlated to the principle of governance and freedom of management and therefore the Company remains committed to ensuring a mature and effective internal control environment that, inter-alia, provides assurance on orderly and efficient conduct of operations, security of assets, prevention and detection of frauds/errors, accuracy and completeness of accounting records and

Management Information Systems, timely preparation of reliable financial information, adherence with relevant statutes and compliance with related party transactions. The Company's Internal Control System is adequate and commensurate with the nature and size of the Company.

11. MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THECOMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIALSTATEMENT RELATE AND THE DATE OF THE REPORT:

No material changes and commitments affecting the financial position of the Company occurred between the end of the financial year to which this financial statement relates on the date of this report.

12. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:

During the year under review, there has been no such significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.

13. SUBSIDIARIES/JOINT VENTURE/ASSOCIATE COMPANY:

As on March 31, 2024, the Company had the following subsidiaries/Associate/Joint Venture.

S.No. Name of the Subsidiary/ Associate/Joint Venture **Relationship**

1. POCT Science House Pvt. Ltd. **Joint Venture**

The company holds 50% equity stake in POCT Science House Pvt. Ltd., a joint venture entered with Science House Medicals Pvt. Ltd. for providing lab services on Wet Lease Basis Reagent Rental in Government Health facilities in Madhya Pradesh. The Company has reported total turnover of **₹13,192.88 Lakh** for the Financial year ending on 31st March, 2024.

2 **Q-Line Iris Pvt Ltd** **Joint Venture**

The company holds a 50% equity stake in Q-Line Iris Pvt Ltd., a joint venture entered with Infer Radiological and Imaging Services Private Limited for providing Radiological and Imaging Labs, screening centers, research establishments, scan centers, and allied services. The Company has not generated any turnover for the Financial Year ending on 31st March, 2024.

3. Q-Line Nutraceuticals Pvt Ltd. **Subsidiary**

The company holds a 55% equity stake in Q-Line Nutraceuticals Pvt Ltd., a subsidiary established to carry on the business of research, development, manufacturing, and marketing of Nutraceuticals, herbal extracts, probiotics, dietary fibers, natural vitamins, and other similar products. The Company has not generated any turnover for the Financial Year ending on 31st March 2024.

14. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL (KMP) & CHANGES IN THE BOARD OF DIRECTORS:

During the financial year 2023-24, there were no significant changes in the composition of the Board of Directors or the operations of the Company.

However, subsequent to the end of the financial year, **Mrs. Manisha Yadav (DIN: 07046310)** resigned as Director of the Company with effect from 18th April 2024. The requisite documents related to her resignation have been duly filed with the Registrar of Companies.

15. **NUMBER OF MEETING OF THE BOARD & CORPORATE SOCIAL RESPONSIBILITY COMMITTEE:**

During the year 2023-24, the Board of Directors met eighteen times (18) to transact the business of the Company. Five (5) meetings of the Committee were held during Financial Year 2023-24.

16. **DEPOSITS:**

The Company has not invited/ accepted any deposits from the public during the year ended March 31, 2024. There were no unclaimed or unpaid deposits as on March 31, 2024.

17. **CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:**

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule, 8 of The Companies (Accounts) Rules, 2014, is annexed herewith as **"Annexure-I"**.

18. **CORPORATE SOCIAL RESPONSIBILITY:**

Pursuant to the requirement of Section 135 of the Companies Act, 2013, a Corporate Social Responsibility (CSR') committee has been formed by the Company. The CSR Committee of the Board has been formed with three Directors that comprises **Mr. Saurabh Garg**, **Mrs. Amita Garg** and **Mr. Abhay Agrawal**, Directors of the Company.

Role of Corporate Social Responsibility Committee:

The role of the Corporate Social Responsibility Committee is as follows:

1. Review the proposals for CSR projects/programs/activities received from various locations;
2. Approve proposals for various CSR projects/programs/activities
3. Identify the projects/activities to be undertaken by the Company for CSR
4. Recommend to the Board CSR Activities to be undertaken along with detailed plan, modalities of execution, implementation schedule, monitoring process and amount to be incurred on such activities
5. Monitor the CSR Policy of the Company from time to time
6. Ensure compliance of CSR Policy and the Rules
7. Such other functions as may be delegated and/or assigned by the Board from time to time

The Corporate Social Responsibility Committee has formulated and recommended to the Board, a Corporate Responsibility Policy (CSR Policy) indicating the activities to be undertaken by the Company, which has been approved by the Board. The key focus areas of the CSR Policy are under;

(i) **Education**: To work on several educational initiatives to provide quality education, training, skill enhancement for ***improving*** the quality of ***living*** and ***livelihood***. Initiatives are aimed at:

a) Promoting primary and secondary education

b) Imparting Skill development and vocational training

c) Using sports as a tool for development of students in both urban and rural settings

d) Promoting higher education including setting up and supporting skill development centres, Industrial Training Centre.

(ii) **Health:** To address issues around affordability and accessibility of quality healthcare and bring about improvement in awareness and health seeking behaviour in various parts of India, enabling a better living, through initiatives such as:

a) Upgrading Primary, secondary and tertiary care facilities

b) Conducting need-based health camps and providing consultation, medicines etc.

c) Working on maternal and child health

d) Improving healthcare delivery through innovative outreach programmes

g) Working in the areas of Communicable and non-communicable diseases

h) Using technology for training, competency evaluation and clinical decision support for medical professionals with a view to improve quality of healthcare.

(iii) **Environment:** To enable enhanced livelihood and quality of life, promote environment sustainability through various initiatives for:

a) Ecological sustainability

b) Promoting biodiversity

c) Conservation of natural resources

d) Maintaining quality of soil, air and water

e) Promoting renewable energy

f) Developing gardens and river fronts

(iv) **Other Initiatives:** To undertake other need-based initiatives in compliance with Schedule VII of the Companies Act, 2013.

The Company is committed to conducting its business in a socially responsible, ethical, and environmentally friendly manner. It continuously strives to improve the quality of life in the communities within its operational areas. We believe that the sustainable development of our business depends on establishing sustainable, long-lasting, and mutually beneficial relationships with our stakeholders, particularly the communities we engage with.

As a responsible corporate citizen, we recognize our role in the integrated and inclusive development of the country, in partnership with the government, corporates, and civil society/community institutions. Furthermore, we believe that our employees have the potential to contribute not only to our business goals but also to the broader objective of building strong and resilient communities.

The Company is committed to complying with Section 135 of the Companies Act, 2013. Our approach focuses on long-term programmes aligned with community needs. As per the Act, CSR activities may be undertaken directly by the Company or through a registered not-for-profit company, trust, or registered society.

The Annual report on CSR activities is annexed herewith marked as **'Annexure-II'**

19. PERFORMANCE AND FINANCIAL POSITION OF EACH OF THE SUBSIDIARIES, ASSOCIATES, JOINT VENTURE INCLUDED IN THE CONSOLIDATED FINANCIAL STATEMENT:

As of 31st March 2024, the Company had one subsidiary and two joint ventures. Additionally, IQ-Line Private Limited ceased to be a subsidiary of Q-Line Biotech Private Limited with effect from **28th March 2024**, following the transfer of its entire stake to Mr. Saurabh Garg.

A detailed report on the performance and financial position of the subsidiary and joint ventures, along with their respective contributions to the Company's overall performance, is presented in **Form AOC-1 as "Annexure III"**, and forms an integral part of this Report.

20. DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to the requirement under section 134(3)(C) of the Companies Act, 2013 with respect to Directors' Responsibility Statement, it is hereby confirmed that:

a. In the preparation of the annual accounts for the financial year ended 31st March, 2024, the applicable accounting standards had been followed along with proper explanation relating to material departures;

b. the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2024 and of the Surplus and loss of the company for that period;

c. the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

d. the directors have prepared the annual accounts on a going concern basis; and

e. the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

21. PREVENTION OF SEXUAL HARASSMENT OF WOMEN AT WORKPLACE:

The Company has in place a policy on Prevention of Sexual Harassment at Workplace. All employees, consultants, trainees, third parties and/or visitors at all business units or functions of the Company, its subsidiaries and/or its affiliated or group companies are covered by the said policy. The Company is in compliance with the provisions relating to the constitution of an Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

22. DECLARATION BY INDEPENDENT DIRECTORS:

The Company was not required to appoint Independent Directors under Section 149(4) and Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 hence no declaration has been obtained.

23. COMPANY'S POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION INCLUDING CRITERIA FOR DETERMINING QUALIFICATIONS, POSITIVE ATTRIBUTES, INDEPENDENCE OF A DIRECTOR AND OTHER MATTERS PROVIDED UNDER SUB-SECTION (3) OF SECTION 178:

The Company, being a Private Limited Company under the Companies Act, 2013 (including any statutory modification(s) or re-enactments thereof for the time being in force) is not required to constitute a Nomination and Remuneration Committee under Section 178(1) of the Companies Act, 2013 and Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Stakeholders Relationship Committee under Section 178(5) of the Companies Act, 2013.

24. CREDIT RATING ON CREDIT FACILITIES FROM BANK:

Your company's financial discipline and prudence are reflected in the credit ratings assigned by CRISIL. The long-term rating has been affirmed at BBB+ with a stable outlook, while the short-term rating stands at A2.

25. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186:

During the year under review, the Company has complied with the provisions of Section 186 of the Companies Act, 2013, related to loans, guarantees, and investments.

Your Company has investments in the shares of other body corporates and is in compliance with the provisions of Section 186. The details of these investments are as follows (refer to Note No. 10 of the Financial Statements for further details):

Sl. No.	Name of the Company	Number of Shares
1	POCT Science House Pvt Ltd	5,000
2	Q-Line Nutraceuticals Private Limited	5,500
3	Q-Line Iris Private Limited	5,000

Additionally, the Company has provided a corporate guarantee amounting to **₹3 crore to POCT Science House Pvt Ltd.** No loans have been provided by the Company during the year.

26. RELATED PARTY TRANSACTIONS:

Particulars of contracts or arrangements with related parties referred to in sub-section (1) of section 188 are mentioned in the form **AOC-2 as "Annexure IV"**..

27. DISCLOSURES RELATING TO REMUNERATION AS PER THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014:

Details of remuneration paid to managerial personnel, as required under the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, are provided in **Annexure** -V. It is also noted that Directors Mr. Saurabh Garg and Mrs. Amita Garg have voluntarily waived their entire remuneration for the financial year 2023-24.

28. DISCLOSURE WHETHER MAINTAINECE OF COST RECORDS AS SPECIFIED BY CENTRAL GOVERNMENT UNDER SUB SECTION 1 OF SECTION 148 OF COMPANIES ACT 2013 IS REQUIRED BY THE COMPANY AND ACCORDINGLY SUCH RECORDS AND ACCOUNTS ARE MAINTAINED BY THE COMPANY:-

Maintenance of Cost Records as specified by Central Government under sub section 1 of Section 148 of Companies Act 2013 is required by the Company and accordingly such records and accounts are maintained by the Company.

Further, The Company had appointed M/s P S P & Associates (Firm Registration Number 005591) Cost Accountants, to conduct the audit of the cost records of the Company pertaining to the financial year ending March 31, 2024, and duly maintains the Cost Records and get them audited by the Cost Auditor.

29. BUSINESS RISK MANAGEMENT:

Pursuant to section 134 (3) (n) of the Companies Act, 2013 the company has not constituted a business risk management committee.

At present the company has not identified any element of risk which may threaten the existence of the company.

30. COMPLIANCE WITH SECRETARIAL STANDARDS:

The applicable Secretarial Standards, i.e., SS-1 and SS-2 relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively, had been duly complied by the Company.

31. ACKNOWLEDGMENT:

Your Directors take this opportunity to place on record their appreciation and sincere gratitude to the Members of the Company, Bankers and other Financial Institutions, Government of India, State Government, Local Bodies, Customers & Suppliers, of the Company for their valuable support and look forward to their continued co-operation in the years to come.

Your Directors acknowledge the support and co-operation received from the employees at all levels and consultants for their continuous co-operation and assistance in management and day to day operation of the Company.

FOR & ON BEHALF OF THE BOARD OF DIRECTORS OF
Q-LINE BIOTECH PRIVATE LIMITED

Q-LINE BIOTECH PRIVATE LIMITED
Saurabh Garg
Director

Q-LINE BIOTECH PRIVATE LIMITED
Amita Garg
Director

Date: 17.09.2024	**Saurabh Garg**	**Amita Garg**
Place: Lucknow	**Director**	**Director**
	DIN: 02891621	**DIN: 02891610**

ANNEXURE – I

Information under Section 134(3)(m) of the Companies Act, 2013 read with rule 8(3) of the Companies (Accounts) Rules, 2014 and forming part of the Report of the Directors

(A) Conservation of energy-

(i) The steps taken or impact on conservation of energy; The operations of your Company are not energy intensive. However, adequate measures have been initiated to reduce energy consumption.

(ii) The steps taken by the company for utilizing alternate sources of energy; The operations of your Company are not energy intensive.

(iii) the capital investment on energy conservation equipment; -Nil

(B) Technology absorption-

(i) the efforts made towards technology absorption: NIL

(ii) the benefits derived like product improvement, cost reduction, product development or import substitution: Not Applicable

(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year): Not Applicable

(iv) the expenditure incurred on Research and Development: NIL

(C) Foreign exchange earnings and Outgo-

During the financial year 2023-24 the total foreign exchange outgo taken place in the ordinary course of business. NIL

FOR & ON BEHALF OF THE BOARD OF DIRECTORS OF
Q-LINE BIOTECH PRIVATE LIMITED

Q-LINE BIOTECH PRIVATE LIMITED
Saurabh Garg
Director

Q-LINE BIOTECH PRIVATE LIMITED
Amita Garg
Director

Date: 17.09.2024
Place: Lucknow

Saurabh Garg
Director
DIN: 02891621

Amita Garg
Director
DIN: 02891610

ANNEXURE – II

CORPORATE SOCIAL RESPONSIBILITY (CSR)

[Pursuant to clause (o) of sub-section (3) of section 134 of the Act and Rule 9 of the Companies (Corporate Social Responsibility) Rules, 2014]

1. A brief outline of the Company's CSR policy, including overview of projects or programs proposed to be undertaken and a reference to the web-link to the CSR policy and projects or programs: ***Refer Point 18, i.e., Corporate Social Responsibility, of the Board report.***
2. The Composition of the CSR Committee: ***Refer Point 18, i.e., Corporate Social Responsibility, of the Board report.***
3. Average net profit of the company for last three financial years: ***Rs.44,96,25,071.50 /-***
4. Prescribed CSR Expenditure (two per cent of the amount as in item 3 above): ***Rs.* 89,92,501.43/-**
5. Deficit of CSR Expenditure of previous Financial Year 2022-2023: **NIL**
6. Details of CSR spent during the financial year.
   - **a)** Total amount spent for the financial year: ***Rs.* 89,93,535.7/-**
   - **b)** Amount unspent, if any: **NIL**
   - **c)** Surplus Amount arising out of CSR projects from Previous year: **NIL**
   - **d)** Excess Amount spent for the financial year: **Rs.1034.27/-**
   - **e)** Manner in which the amount spent during the financial year is detailed below.

S.No	Name of the Project	Items from the list of activities in schedule VII to the act	Local Area(Y/N)	Location of the Project		Amount spent for the Project (RS)	Mode of Implementation-Direct (Y/N)	Mode of Implementation-Through implementing Agency	
				state	District			Name	CSR Reg No
1	Upgrading Healthcare facilities	(i)	Yes	Uttar Pradesh	Gorakhpur	20,19,250	Y	NA	NA
2	Upgrading Healthcare facilities	(i)	Yes	Uttar Pradesh	Lucknow	2,00,000	N	Bhaurao Devras Seva Nyas	CSR00004454
3	Eradication of Poverty	(i)	Yes	Uttar Pradesh	Lucknow	2,14,285.70	Y	NA	NA
4	Upgrading Healthcare facilities	(i)	Yes	Uttar Pradesh	Lucknow	23,10,000	Y	NA	NA

5	Promoting Education	(ii)	No	Uttara Khand	Dehradun	30,00,000	N	Intellectual People Achievement Federation	CSR00031840
6	Contribution to PM Care Fund	(viii)	NA	Delhi	New Delhi	12,50,000	N	PM CARE Fund	NA
TOTAL						89,93,535.7			

7. In case the Company has failed to spend two per cent of the average net profit of the last three financial years or any part thereof, the Company shall provide the reasons for not spending the amount in its Board report: NA

8. Responsibility Statement of the CSR Committee: The implementation and monitoring of CSR Policy, is in compliance with CSR objectives and Policy of the Company.

FOR & ON BEHALF OF THE BOARD OF DIRECTORS OF Q-LINE BIOTECH PRIVATE LIMITED

Q-LINE BIOTECH PRIVATE LIMITED

Saurabh Garg

Director

Q-LINE BIOTECH PRIVATE LIMITED

Amita Garg

Director

Date: 17.09.2024
Place: Lucknow

Saurabh Garg
Director
DIN: 02891621

Amita Garg
Director
DIN: 02891610

ANNEXURE - III

FORM NO. AOC-1

Statement containing salient features of the financial statement of Subsidiaries/associate companies/joint ventures

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Part "A": Subsidiaries

S.No.	Particulars	Details
1.	Name of the subsidiary	Q-Line Nutraceuticals Private Limited
2.	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Same as Holding Company
3.	Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries.	INR
4.	Share capital	1,00,000
5.	Reserves & Surplus	(38,15,346.87)
6.	Total assets	93,70,757.13
7.	Total Liabilities	1,30,86,104
8.	Investments	-
9.	Turnover	NIL
10.	Profit before taxation	**(38,15,346.87)**
11.	Provision for taxation	NIL
12.	Profit after taxation	**(38,15,346.87)**
13.	Proposed Dividend	NIL
14.	% of shareholding	55%

Notes: The following infomation shall be furnished at the end of the statement:

1. Names of subsidiaries which are yet to commence operations - **NIL**
2. Names of subsidiaries which have been liquidated or sold during the year - **IQ-Line Private Limited ceased to be the subsidiary of Q-Line Biotech Private Limited w.e.f from 28th March 2024 by transferring its full stake to Mr. Saurabh Garg .**

Part "B": Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures

Name of Associates/Joint Ventures	**POCT Science House Private Limited**	**Q- LINE IRIS PRIVATE LIMITED**
1. Latest audited Balance Sheet Date	31st March 2024	31ST March 2024
2. Number Shares of Associate/Joint Ventures held by the company on the year end	5,000	5,000
Amount of Investment in Associates/Joint Venture	Rs. 50,000	Rs. 50,000
Extend of Holding %	50%	50%
3. Description of how there is significant influence	50% stake in the Company	50% stake in the Company
4. Reason why the associate/joint venture is not consolidated	Not Applicable	Not Applicable
5. Networth attributable to Shareholding as per latest audited Balance Sheet	57,01,74,000	66,600
6. Profit / Loss for the year	**25,78,50,279.05**	**(33,400.00)**
i. Considered in Consolidation	-	-
i. Not Considered in Consolidation	**25,78,50,279.05**	**(33,400.00)**

FOR & ON BEHALF OF THE BOARD OF DIRECTORS OF
Q-LINE BIOTECH PRIVATE LIMITED

Q-LINE BIOTECH PRIVATE LIMITED
Saurabh Garg
Director

Q-LINE BIOTECH PRIVATE LIMITED
Amita Garg
Director

Date: 17.09.2024
Place: Lucknow

Saurabh Garg
Director
DIN: 02891621

Amita Garg
Director
DIN: 02891610

ANNEXURE - IV

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the Company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. **Details of contracts or arrangements or transactions not at Arm's length basis:** There were no contracts or arrangements or transactions entered in to during the year ended March 31, 2024, which were not at arm's length basis.

2. **Details of contracts or arrangements or transactions at Arm's length basis:**

Name(s) of the related party	Nature of Relationship	Duration of contract	Salient terms	Dates of Approval by the Board	Amount Rs.	Amount paid as advances, if any
Nature of Contract: SALES OF GOODS						
Heidelco Medicore Pvt. Ltd.	Associated Enterprise	-	-	3.04.2023	3,82,362.55	Nil
POCT Services	Associated Enterprise	-	-	3.04.2023	1,19,45,78,782	N
Nature of Contract: RENT PAID						
Heidelco Medicore Pvt. Ltd.	Associated Enterprise	11 Month	Rent Agreement	1.07.2023	5,00,004.00	Nil
POCT Services	Associated Enterprise	11 Month	Rent Agreement	03.06.2023	2,40,000	Nil
Nature of Contract: RENT INCOME						
POCT Quality & Skill Development Foundation	Associated Enterprise	11 Month	Rent Agreement	03.04.2023	1,20,000	Nil
POCT Services	Associated Enterprise	11 Month	Rent Agreement	23.08.2023	7,20,000	Nil

POCT Science House Pvt. Ltd.	Associated Enterprise	11 Month	Rent Agreement	15.01.2024	1,20,000	Nil
NATURE OF CONTRACT: SALARY, INCENTIVE & EXPENSES						
Kuldeep Chowdhry	Director	-	-	-	54,31,344	Nil
Ajay Kumar Mahanty	Director	-	-	-	76,59,000	Nil
Manisha Yadav	Director	-	-	-	18,00,000	Nil
Ayush Garg	Director	-	-	-	1,48,00,000	Nil
Amit Agarwal	Relative	-	-	-	42,00,000	Nil
Nature of Contract: PURCHASE OF GOODS						
Heidelco Medicore Pvt. Ltd.	Associated Enterprise	-	-	3.04.2023	82,050	Nil
IQ-Line Private Limited	Associated Enterprise	-	-	3.04.2023	1,09,88,750	Nil
POCT Services	Associated Enterprise	-	-	3.04.2023	5,20,26,198.94	Nil
Nature of Contract: CIVIL WORK						
ASG Buildtech Pvt. Ltd.	Associated Enterprise	-	-	3.04.2023	88,75,973.56	Nil
Nature of Contract: Advances						
Q-Line Innovations Pvt.Ltd.	Associated Enterprise	-	-	09.08.2023	1,78,45,242.00	Nil
SperogenX Biosciences Pvt Ltd	Associated Enterprise	-	-	10.05.2019	28,18,127.00	Nil
Q-Line Healthcare Pvt. Ltd.	Associated Enterprise	-	-	09.08.2023	3,80,00,000	Nil
Q-Line Nutraceuticals Pvt. Ltd.	Associated Enterprise	-	-	03.06.2023	1,24,67,000	Nil
POCT Science House Private Limited	Associated Enterprise	-	-	20.02.2023	5,30,00,000	Nil
Heidelco Medicore Private Limited	Associated Enterprise	-	-	3.06.2023	1,50,00,000	Nil

IQ-Line Private Limited	Associated Enterprise	-	-	03.04.2023	1,50,64,000	Nil
Science House Medicals Private Limited	Associated Enterprise	-	-	24.09.2019	37,50,000	Nil
Nature of Contract: Travelling Expenses						
Ajay Kumar Mahanty	Director	-	-	3.04.2023	4,94,622.00	Nil
Ayush Garg	Director	-	-	3.04.2023	3,20,000.00	Nil
Amit Agarwal	Relative	-	-	3.04.2023	2,22,927.00	Nil
Kuldeep Chowdhry	Director	-	-	3.04.2023	6,39,954.00	Nil
Nature of Contract: Consultancy Purchase						
Q-Line Innovations Private Limited	Associated Enterprise	-	-	3.04.2023	63,42,500	Nil

FOR & ON BEHALF OF THE BOARD OF DIRECTORS OF Q-LINE BIOTECH PRIVATE LIMITED

Q-LINE BIOTECH PRIVATE LIMITED
Saurabh Garg
Director

Q-LINE BIOTECH PRIVATE LIMITED
Amita Garg
Director

Date: 17.09.2024
Place: Lucknow

Saurabh Garg
Director
DIN: 02891621

Amita Garg
Director
DIN: 02891610

Annexure V

REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

S. No.	Name of Employee	Designation	Remuneration (In INR)	Date of Employment	Age	Equity Shares held
1	Manisha Yadav	Director	18,00,000	12-01-2015	53	NIL
2	Kuldeep Chowdhry	Director	54,31,344	12-01-2015	52	NIL
3	Ajay Kumar Mahanty	Director	76,59,000	12-01-2015	47	4.76%

FOR & ON BEHALF OF THE BOARD OF DIRECTORS OF
Q-LINE BIOTECH PRIVATE LIMITED

Q-LINE BIOTECH PRIVATE LIMITED
Saurabh Garg
Director

Q-LINE BIOTECH PRIVATE LIMITED
Amita Garg
Director

Date: 17.09.2024
Place: Lucknow

Saurabh Garg
Director
DIN: 02891621

Amita Garg
Director
DIN: 02891610